ACCESSWIRE

AlzeCure Pharma

Share
AlzeCure Presents Novel Alzstatin Data at the 11th Pharmaceutical Profiling Meeting

STOCKHOLM, SWEDEN / ACCESSWIRE / January 4, 2022 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that an abstract with new promising preclinical Alzstatin data has been accepted for a poster presentation at the 11th Symposium on Pharmaceutical Profiling in Drug Discovery and Development on January 27, 2022, at the Humanities Theatre, English Park Campus, Uppsala.

The poster, titled Development of novel gamma-secretase modulators for the treatment of Alzheimer's disease , will be presented by Dr. Maria Backlund at the 11th Symposium on Pharmaceutical Profiling in Drug Discovery and Development, hosted by Uppsala University's Department of Pharmacy. Other authors include Sanja Juric, Dr. Johan Sandin, CSO at AlzeCure and Dr. Gunnar Nordvall, Head of Chemistry at AlzeCure.

The aim of the work was to explore the effect of AlzeCure's compound AC-0027875 on Aβ42 reduction, i.e reducing the production of toxic amyloid beta, in animals as well as to assess its pharmacokinetic properties. AC-0027875 is a novel potent small molecule γ-secretase modulator and part of AlzeCure's research platform Alzstatin. γ-Secretase modulators, so called GSMs, represent a promising class of Aβ42-lowering anti-amyloidogenic compounds for treatment of Alzheimer's disease. GSMs exhibit several key features that make them suitable as a disease-modifying or preventive treatment of presymptomatic Alzheimer's disease.

"It is established that Aβ plays a key pathogenic role in Alzheimer's and begins to accumulate in the brain years before clear symptoms develop. Although these are still preclinical data, it's encouring to see the results indicating that GSMs, such as our AC-0027875, reduces toxic Aβ42 production making them highly promising as therapy for the treatment of Alzheimer's disease," said Johan Sandin, CSO at AlzeCure Pharma.

"With Alzstatin we at Alzecure want to offer a preventive and disease modifying treatment against Alzheimer's in the form of a oral therapy, which is non-invasive for patients, and the progress we are making is encouraging," said Martin Jönsson, CEO at AlzeCure Pharma.

The abstract and the poster will be available on AlzeCure's website after the presentation ( https://www.alzecurepharma.se/en/publications ).

For more information, please contact

Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .

About Alzstatin
AlzeCure's disease-modifying research platform, Alzstatin, consisting of disease-modifying and preventive drug candidates, focuses on reducing the production of toxic amyloid beta (Aβ), such as Aβ42, in the brain. Aβ42 plays a key pathological role in Alzheimer's and begins to accumulate in the brain years before clear symptoms develop. The drug candidates in the Alzstatin platform modulate the function of the enzyme gamma secretase. Gamma secretase acts like a pair of scissors and cuts Aβ42 out from a longer protein known as APP. The sticky Aβ42 clumps together giving rise to the amyloid plaque so typical of Alzheimer's disease. The candidates in the Alzstatin platform affect enzyme function so that it instead cuts out shorter forms of the Aβ peptide, Aβ37 and Aβ38, which in addition to them not being sticky and not forming aggregates, also have a restrictive effects on Aβ42 aggregates already formed. This means the drug candidates in the Alzstatin platform have two separate but synergistic effects that together contribute to a stronger anti-amyloidogenic - and thus more potent - disease-modifying effect. This specific mechanism of action differentiates it from biological therapies, e.g. antibodies. Moreover, small molecules such as Alzstatin, have several other advantages, including easy and non-invasive administration as tablets or capsules. Small molecules will also generally pass more readily through the blood-brain barrier to reach its target, the brain.

Attachments

AlzeCure presents novel Alzstatin data at the 11th Pharmaceutical Profiling meeting

SOURCE: AlzeCure Pharma



View source version on accesswire.com:
https://www.accesswire.com/680846/AlzeCure-Presents-Novel-Alzstatin-Data-at-the-11th-Pharmaceutical-Profiling-Meeting

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESSWIRE

DK

Subscribe to releases from ACCESSWIRE

Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESSWIRE

Central Bank of Bahrain Grants Crypto.com Payment Service Provider Licence19.9.2024 13:00:00 CEST | Press release

MANAMA, BAHRAIN / ACCESSWIRE / September 19, 2024 / The Central Bank of Bahrain today granted Crypto.com full approval to provide payment service provider (PSP) services through its subsidiary registered in the Kingdom of Bahrain under the commercial name "FORIS GFS BH B.S.C. CLOSED", adding to the company's significant regulatory milestones in the region. The PSP licence will allow Crypto.com to expand its offerings of e-money and fiat-based payment services regionally, including the launch of its world-renowned prepaid cards. "With its extensive international presence and an earned reputation for regulatory compliance, we are delighted that Crypto.com has chosen the Kingdom of Bahrain as a destination for investment, which will further bolster Bahrain's ability to deliver on its vision of developing a digital-first, resilient economy that celebrates innovation and progress," said H.E. Noor bint Ali Alkhulaif, Minister of Sustainable Development, Chief Executive of Bahrain Economic De

Taurus secures "Best Digital Assets Solution" at 2024 Global BankTech Awards19.9.2024 09:20:00 CEST | Press release

Swiss Fintech commended for secure custody, asset tokenization services, and its marketplace for digital assets LONDON, UK and GENEVA, SWITZERLAND / ACCESSWIRE / September 19, 2024 - Taurus, the Swiss-regulated global leader in digital asset infrastructure for banks, has been named "Best Digital Assets Solution" at the prestigious Global BankTech Awards 2024 - the premier awards programme for the fintech industry. Taurus has been recognized for its comprehensive and modular infrastructure that enables financial institutions to issue, custody, and trade digital assets, including tokenized assets, cryptos, NFTs, and digital currencies. "Taurus offers enterprise-level digital asset infrastructure for the issuance, custody, and trading of all digital assets, encompassing cryptocurrencies, tokenized securities, and digital currencies," said Mobasher Kazmi, Head of Research for The Digital Banker. "Commendably, its suite of products comprising Taurus-PROTECT™ for secure custody, Taurus-CAPIT

Silicon Foundry and Kearney Introduce 'The Collective // Supply Chain' to Help Organizations Identify Trends and Solutions for Future-Proof Supply Chains19.9.2024 09:00:00 CEST | Press release

The immersive program will provide supply chain professionals with frontline insights, targeted connectivity, and actionable opportunities, enabling them to make strategic decisions that strengthen and accelerate their supply chain initiatives. SAN FRANCISCO, CA / ACCESSWIRE / September 19, 2024 / Silicon Foundry, a Kearney-owned innovation advisory firm, today announced the launch of The Collective // Supply Chain, a year-long, membership-based program providing supply chain professionals with access to a curated flow of real-time insights, an executive peer community, expert consultations, exclusive events, and a presence in the heart of Silicon Valley. The Collective // Supply Chain addresses the challenges of navigating modern supply chain disruptions, optimizing processes, and integrating advanced technologies to achieve operational excellence. Kearney's recent COO Innovation Radar survey found that 90%+ of corporations increased their innovation budgets in the past year. High-ROI

MGO Global's CEO Invited by Argentinian Consulate in New York to Join President of the Argentine Republic to Ring Morning Bell at NYSE19.9.2024 08:30:00 CEST | Press release

MIAMI, FL and LONDON, UK / ACCESSWIRE / September 19, 2024 / MGO Global Inc. (NASDAQ:MGOL), a digitally-native, lifestyle brand portfolio company, ("MGO," "MGO Global" or the "Company"), today announced Maximiliano Ojeda, Co-Founder, Chairman and CEO of MGO, has been invited by the Consulate General of Argentina in New York to join His Excellency Javier Milei, President of the Argentine Republic, to ring the opening bell at the New York Stock Exchange on Monday, September 23, 2024. In the U.S. to participate in the United Nations General Assembly this week, President Milei will deliver a major economic address to all invited guests in the NYSE Board Room preceding the bell ringing ceremony that will open the financial markets. Ojeda stated, "I feel very honored to be among the other business executives who have been invited to participate in this important occasion at the NYSE. Given my Argentinian heritage and the deep economic ties and shared interests of the United States and Argent

U.S. Polo Assn.’s Fall-Winter 2024 Collection Launches from the Rockies19.9.2024 07:00:00 CEST | Press release

Sport-Inspired Brand's Vibrant, Seasonal Collection Includes Perfect Gifting Items for the Holidays WEST PALM BEACH, FL / ACCESSWIRE / September 19, 2024 / U.S. Polo Assn., the official brand of the United States Polo Association (USPA), proudly announces the launch of the sporty, classic, and colorfully vibrant Fall-Winter 2024 Collection. Inspired by the scenic beauty and historic charm of Salt Lake City, Utah, this Fall-Winter collection is a tribute to the season's warm, festive spirit and the joy of giving. The collection's global photoshoot is set against stunning snow-capped mountain vistas and nestled in the foothills of the Rocky Mountains. Models and polo players alike are adorned in the latest styles of U.S. Polo Assn., showcasing family and friends enjoying the great outdoors and cozying up by the fireside in Salt Lake City. The collection features an extensive range of cold-weather classics such as knitted sweater polos, quilted jackets, cable-knit cardigans, and cozy flan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye